EP3253797A4 - Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof - Google Patents

Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof Download PDF

Info

Publication number
EP3253797A4
EP3253797A4 EP16747125.9A EP16747125A EP3253797A4 EP 3253797 A4 EP3253797 A4 EP 3253797A4 EP 16747125 A EP16747125 A EP 16747125A EP 3253797 A4 EP3253797 A4 EP 3253797A4
Authority
EP
European Patent Office
Prior art keywords
chemokine
compositions
making
fusion polypeptides
immunoglobulin fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16747125.9A
Other languages
German (de)
French (fr)
Other versions
EP3253797A1 (en
Inventor
James W. Lillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jyant Technologies Inc
Original Assignee
Jyant Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/612,884 external-priority patent/US9249204B2/en
Application filed by Jyant Technologies Inc filed Critical Jyant Technologies Inc
Publication of EP3253797A1 publication Critical patent/EP3253797A1/en
Publication of EP3253797A4 publication Critical patent/EP3253797A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
EP16747125.9A 2015-02-03 2016-02-02 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof Withdrawn EP3253797A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/612,884 US9249204B2 (en) 2011-06-01 2015-02-03 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
PCT/US2016/016191 WO2016126719A1 (en) 2015-02-03 2016-02-02 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Publications (2)

Publication Number Publication Date
EP3253797A1 EP3253797A1 (en) 2017-12-13
EP3253797A4 true EP3253797A4 (en) 2018-10-03

Family

ID=56564605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16747125.9A Withdrawn EP3253797A4 (en) 2015-02-03 2016-02-02 Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Country Status (3)

Country Link
EP (1) EP3253797A4 (en)
CN (1) CN107207603A (en)
WO (1) WO2016126719A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737689A4 (en) * 2018-01-09 2021-12-01 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
ES2955511T3 (en) * 2018-05-14 2023-12-04 Werewolf Therapeutics Inc Activatable interleukin 2 polypeptides and methods of use thereof
AU2019271819A1 (en) * 2018-05-15 2021-01-14 Crage Medical Co., Limited Genetically engineered cell and application thereof
EP4013774A1 (en) * 2019-08-13 2022-06-22 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists
CN111440244B (en) * 2020-04-09 2021-03-16 诺未科技（北京）有限公司 Metastatic cancer vaccine targeting VEGFR2
CN113318120A (en) * 2021-06-07 2021-08-31 昆明医科大学第二附属医院 Application of miR4512 and CXCL2 in autoimmune diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037305A1 (en) * 2003-10-16 2005-04-28 Applied Research Systems Ars Holding N.V. Therapeutic uses of chemokine variants
US20070036750A1 (en) * 2005-08-12 2007-02-15 Schering Corporation MCP1 fusions
US20100196406A1 (en) * 2007-06-04 2010-08-05 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
US20120308565A1 (en) * 2011-06-01 2012-12-06 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130323245A1 (en) * 2011-06-01 2013-12-05 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2347340T3 (en) * 2004-09-13 2010-10-28 Genzyme Corporation MULTIMERICAL CONSTRUCTIONS.
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037305A1 (en) * 2003-10-16 2005-04-28 Applied Research Systems Ars Holding N.V. Therapeutic uses of chemokine variants
US20070036750A1 (en) * 2005-08-12 2007-02-15 Schering Corporation MCP1 fusions
US20100196406A1 (en) * 2007-06-04 2010-08-05 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
US20120308565A1 (en) * 2011-06-01 2012-12-06 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130323245A1 (en) * 2011-06-01 2013-12-05 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US20130330337A1 (en) * 2011-06-01 2013-12-12 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016126719A1 *

Also Published As

Publication number Publication date
WO2016126719A1 (en) 2016-08-11
EP3253797A1 (en) 2017-12-13
CN107207603A (en) 2017-09-26

Similar Documents

Publication Publication Date Title
EP3347472A4 (en) Compositions comprising cyp76ad1- clade polypeptides and uses thereof
EP3377307A4 (en) Structural composition and method
EP3356308A4 (en) Calcium-silicate-based porous particles, composition, method of making and use thereof
EP3455263A4 (en) Cd40l-fc fusion polypeptides and methods of use thereof
EP3253797A4 (en) Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
EP3373910A4 (en) Echinomycin formulation, method of making and method of use thereof
IL275435A (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
EP3212290A4 (en) Serpin fusion polypeptides and methods of use thereof
EP3354653A4 (en) Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof
EP3510134A4 (en) Cleaning composition, method of making and use thereof
EP3092248A4 (en) Fusion polypeptides and methods of use
EP3300501A4 (en) Novel compositions, uses and methods for making them
EP3391897A4 (en) Hemostatic composition and hemostatic method using hemostatic composition
EP3323825A4 (en) Polypeptide compound and preparation method and use thereof
EP3315508A4 (en) Polypeptide compound and preparation method and use thereof
EP3146968A4 (en) K2 composition, preparation method therefor, and application thereof
EP3202778A4 (en) Conotoxin polypeptide kappa-cptx-bt105, and method for preparation thereof and application thereof
EP3392263A4 (en) Polypeptide compound, preparation method therefor and use thereof
EP3349748A4 (en) Composition and methods thereof
EP3337518A4 (en) Bag3 compositions and methods
EP3319930A4 (en) Methods and compositions for the stabilizaton of proteins
EP3394175A4 (en) Composition, method of making composition, and article
EP3394174A4 (en) Composition, method of making composition, and article
EP3132790A4 (en) Exenatide-containing composition and preparation method therefor
EP3202775A4 (en) Conotoxin polypeptide kappa-cptx-bt104, and method for preparation thereof and application thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20180524BHEP

Ipc: A61K 39/395 20060101ALI20180524BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20180904

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101AFI20180829BHEP

Ipc: A61K 39/395 20060101ALI20180829BHEP

17Q First examination report despatched

Effective date: 20200203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200616